Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE

Media type: E-Article

Title: Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE

Contributor: Eschbach, Ralf Stefan [Author]; Hofmann, Markus [Author]; Späth, Lukas [Author]; Sheikh, Gabriel T. [Author]; Delker, Astrid [Author]; Lindner, Simon [Author]; Jurkschat, Klaus [Author]; Wängler, Carmen [Author]; Wängler, Björn [Author]; Schirrmacher, Ralf [Author]; Tiling, Reinhold [Author]; Brendel, Matthias [Author]; Wenter, Vera [Author]; Dekorsy, Franziska J. [Author]; Zacherl, Mathias J. [Author]; Todica, Andrei [Author]; Ilhan, Harun [Author]; Grawe, Freba [Author]; Cyran, Clemens C. [Author]; Unterrainer, Marcus [Author]; Rübenthaler, Johannes [Author]; Knösel, Thomas [Author]; Paul, Tanja [Author]; Boeck, Stefan [Author]; Westphalen, Christoph Benedikt [Author]; Spitzweg, Christine [Author]; Auernhammer, Christoph J. [Author]; Bartenstein, Peter [Author]; Unterrainer, Lena M. [Author]; Beyer, Leonie [Author]

Published: 30 January 2023

Language: English

DOI: 10.3389/fonc.2023.992316

Identifier:

Keywords: Molecular Imaging ; NET ; PET/CT ; Somatostatin analogues ; somatostatin receptor

Origination:

Footnote: Im Titel ist die Zahl 18 hochgestellt

Description: Purpose: Somatostatin analogues (SSA) are frequently used in the treatment of neuroendocrine tumours. Recently, [18F]SiTATE entered the field of somatostatin receptor (SSR) positron emission tomography (PET)/computed tomography (CT) imaging. The purpose of this study was to compare the SSR-expression of differentiated gastroentero-pancreatic neuroendocrine tumours (GEP-NET) measured by [18F]SiTATE-PET/CT in patients with and without previous treatment with long-acting SSAs to evaluate if SSA treatment needs to be paused prior to [18F]SiTATE-PET/CT. Methods: 77 patients were examined with standardised [18F]SiTATE-PET/CT within clinical routine: 40 patients with long-acting SSAs up to 28 days prior to PET/CT examination and 37 patients without pre-treatment with SSAs. Maximum and mean standardized uptake values (SUVmax and SUVmean) of tumours and metastases (liver, lymphnode, mesenteric/peritoneal and bones) as well as representative background tissues (liver, spleen, adrenal gland, blood pool, small intestine, lung, bone) were measured, SUV ratios (SUVR) were calculated between tumours/metastases and liver, likewise between tumours/metastases and corresponding specific background, and compared between the two groups. Results: SUVmean of liver (5.4 ± 1.5 vs. 6.8 ± 1.8) and spleen (17.5 ± 6.8 vs. 36.7 ± 10.3) were significantly lower (p < 0.001) and SUVmean of blood pool (1.7 ± 0.6 vs. 1.3 ± 0.3) was significantly higher (p < 0.001) in patients with SSA pre-treatment compared to patients without. No significant differences between tumour-to-liver and specific tumour-to-background SUVRs were observed between both groups (all p > 0.05). Conclusion: In patients previously treated with SSAs, a significantly lower SSR expression ([18F]SiTATE uptake) in normal liver and spleen tissue was observed, as previously reported for 68Ga-labelled SSAs, without significant reduction of tumour-to-background contrast. Therefore, there is no evidence that SSA treatment needs to be paused prior to [18F]SiTATE-PET/CT.

Access State: Open Access

Search in field:

Recently searched for: